The Pharma Letter2h
Gilead’s Livdelzi reduced pruritus severity in PBC participants
US antiviral giant Gilead Sciences on Friday unveiled two-and-a-half-year interim analysis from the ongoing Phase III ASSURE ...
The Pharma Letter19h
Positive new data for Ipsen’s Iqirvo
French drugmaker Ipsen (Euronext: IPN) announced late-breaking data for Iqirvo (elafibranor 80mg tablets) from an interim ...